Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer | Zendy

Giancarlo Agnelli | Zendy; Cecilia Becattini | Zendy; Guy Meyer | Zendy; Andrés J. Muñoz Martín | Zendy; Menno V. Huisman | Zendy; Jean M. Connors | Zendy; Alexander Cohen | Zendy; Rupert Bauersachs | Zendy; Benjamin Brenner | Zendy; Adam Torbicki | Zendy; María Rosales Sueiro | Zendy; Catherine Lambert | Zendy; Gualberto Gussoni | Zendy; Mauro Campanini | Zendy; Andrea Fontanella | Zendy; Giorgio Vescovo | Zendy; Melina Verso | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Author(s) -

Giancarlo Agnelli,

Cecilia Becattini,

Guy Meyer,

Andrés J. Muñoz Martín,

Menno V. Huisman,

Jean M. Connors,

Alexander Cohen,

Rupert Bauersachs,

Benjamin Brenner,

Adam Torbicki,

María Rosales Sueiro,

Catherine Lambert,

Gualberto Gussoni,

Mauro Campanini,

Andrea Fontanella,

Giorgio Vescovo,

Melina Verso

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1915103

Subject(s) - medicine , apixaban , hazard ratio , edoxaban , pulmonary embolism , surgery , rivaroxaban , venous thrombosis , randomized controlled trial , deep vein , confidence interval , anesthesia , warfarin , thrombosis , atrial fibrillation

Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research